fda safety communication semaglutide naion 2025 Once Again Linked to in Largest Study to Date Small NAION Risk from GLP-1

It contains L-Carnitine L-Tartrate, known for assisting fat conversion into usable energy, and Chromium Picolinate, which helps regulate metabolic balance

Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs)

The deadline for state-licensed pharmacies and physicians compounding under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) is April 22, 2025

This makes it a promising option for managing type 2 diabetes and prediabetic metabolic dysfunction

GLP-1 (Semaglutide): Reduces appetite Slows gastric emptying Increases satiety Supports sustainable calorie reduction Average weight loss: Up to 15% in 68 weeks (NEJM 2021) GLP-1 + GIP (Tirzepatide): GLP-1 + GIP synergy boosts insulin sensitivity Enhances metabolic balance Further suppresses appetite and cravings Average weight loss: Up to 21% in 72 weeks (SURMOUNT-1) Compounded vs

Built for groups that want fewer denials, CMS-0057-F readiness, and daily exception visibility